Roivant Sciences Ltd. Common Shares
ROIV · Nasdaq
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Total Revenue | $8.26M | $29.05M | $32.71M | $31.53M | $55.29M | $23.80M |
| Research & Development | $681.81M | $550.41M | $439.91M | $454.06M | $483.04M | $236.63M |
| Selling, General & Administrative | $610.47M | $591.41M | $687.44M | $600.51M | $775.03M | $259.88M |
| Operating Expenses | $1.29B | $1.14B | $884.09M | $938.29M | $1.41B | $1.09B |
| Operating Income | -$515.07M | -$1.00B | $4.50B | -$906.76M | -$1.35B | -$1.07B |
| Interest Expense | — | — | $34.78M | $27.97M | $7.04M | $2.81M |
| Other Income / (Expense) | $4.01M | -$10.72M | -$13.56M | -$486.00K | $3.24M | -$8.70M |
| Income Before Taxes | -$264.58M | -$681.59M | $4.57B | -$884.99M | -$923.75M | -$898.55M |
| Provision for Income Taxes | $133.33M | $48.17M | $21.50M | $4.08M | $369.00K | $1.69M |
| Net Income | -$299.77M | -$171.98M | $4.35B | -$1.01B | -$845.26M | -$809.23M |
| Basic EPS | -$0.43 | -$0.24 | $5.55 | -$1.42 | -$1.26 | — |
| Diluted EPS | -$0.54 | -$0.24 | $5.23 | -$1.42 | -$1.26 | — |
| Basic Shares Outstanding | 693.86M | 725.40M | 783.25M | 712.79M | 669.75M | — |
| Diluted Shares Outstanding | 693.86M | 725.40M | 831.05M | 712.79M | 669.75M | — |
Analyst Estimates
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Mar 2027 | -$2.00 | -$2.00 | -$2.00 | 1 | ↑0 ↓0 |
| Mar 2028 | -$2.23 | -$2.23 | -$2.23 | 1 | ↑0 ↓0 |
